

Mild To Severe Traumatic Brain Injury In Children: Altered Cytokines Reflect Severity

Emer Ryan (✉ msemerryan@gmail.com)

Trinity College Dublin: The University of Dublin Trinity College <https://orcid.org/0000-0001-5430-5115>

Lynne Kelly

Trinity College Dublin: The University of Dublin Trinity College

Catherine Stacey

Trinity College Dublin School of Medicine

Dean Huggard

Trinity College Dublin School of Medicine

Eimear Duff

Trinity College Dublin School of Medicine

Danielle McCollum

Trinity College Dublin School of Medicine

Ann Leonard

Tallaght Hospital: Tallaght University Hospital

Gerard Boran

Trinity College Dublin School of Chemistry

Dermot R Doherty

Children's Health Ireland

Turlough Bolger

Children's Health Ireland at Tallaght

Eleanor J Molloy

Trinity College Dublin School of Medicine

Research

Keywords: Traumatic Brain injury, Concussion, Inflammation, cytokines, innate immunity

Posted Date: June 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-551290/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Neuroinflammation on February 7th, 2022. See the published version at <https://doi.org/10.1186/s12974-022-02390-5>.

Abstract

Background: Paediatric traumatic brain injury (TBI) is recognised to have significant longer-term neurocognitive effects. Childhood is a time of high risk for head injury. Functional recovery is variable with a combination of any or all of physical, cognitive and emotional impairment. Immune activation and alteration in cytokine levels are present following TBI which may differ from adults.

Methods: Pro and anti-inflammatory cytokines including Interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, IL-17A, Tumor Necrosis Factor (TNF)- α and Interferon (IFN)- γ were examined at baseline and following *in vitro* treatment with endotoxin of whole blood, in the following children: severe TBI (sTBI: initial Glasgow coma scale(GCS) \leq 8), mild TBI (mTBI; GCS 14/15) at 0-4d and at 10-14d post-TBI and compared to healthy age-matched controls

Results: The study enrolled 208 children including 110 with TBI cohort (n=104 mild; 6 severe) and controls (n=98). At baseline all children with TBI had increased IL-6. The mTBI group had significantly increased IFN- γ versus controls. In sTBI at baseline, IFN- γ was decreased compared to controls. At baseline IL-8, IL-10, IL-17A, and TNF- α were decreased in mTBI compared to controls. This persisted at two weeks post-mTBI. The AUC for detecting mTBI was 0.801 CI (0.73 – 0.86) using IL6/IL10 ratio. mTBI showed a greater fold change in IL-8 and TNF- α in response to endotoxin stimulation, a response that persisted at two weeks. Children with sTBI did not have a significant IL-6 response to endotoxin but did show an increase in IL-17A.

Conclusion: Children with all TBI including mTBI show altered cytokine profiles and altered endotoxin responses. Although cytokines increased in sTBI especially in response to endotoxin, suppressed responses were found in mTBI coupled with persistent immune dysfunction post injury.

Background

Traumatic brain injury is a global cause of preventable death and disability and a common presentation to the emergency department. Each year three percent of all children under 5 years will present to the emergency department with head injury [1]. In England and Wales, of 1.4 million emergency department visits a year for head injuries, half are under 15 years. Mild traumatic brain injury (mTBI) accounts for the majority (90%) of traumatic brain injury [2]. The consequences of TBI in children are catastrophic, particularly, before neuronal networks are laid down. Despite this there are no therapeutic agents. Inflammatory responses vary across the lifespan. Exploring the age-related inflammatory component of TBI is important for our understanding and therapeutic interventions.

Neuronal injury results in a cascade of neuroinflammation with activation of glia, the release of inflammatory mediators and the recruitment of systemic immune cells. Animal models have demonstrated acute and chronic effects on immune function following brain injury [3]. Following neonatal brain injury, children at school age had persistently altered cytokine profiles with elevated serum IL-2, IL-6 and IL-8 [4]. In the acute stage of severe traumatic brain injury IL-6 and IL-8 show an early

increase [5]. Cerebrospinal fluid showed high levels of IL-6 and IL-10 in earlier TBI studies in children[6]. Serum IL-6, IL-8 and IL-10 can predict poorer neurological outcomes in severe paediatric TBI [7] and increased IL-6 in mild TBI was significantly associated with the duration of symptoms in post concussive syndrome in high school and college football players [8]. Post injury altered immune function also plays a role in the high rate of nosocomial infection in children with TBI[9].

Both IFN- γ and IL-4 have been studied in the context of TBI but no study has generated conclusive evidence in their roles in TBI [10]. Interleukin-10 is known for its anti-inflammatory properties. In IL-10 knockout mice brain injury lesions are larger than wild-type mice [11] and increased IL-10 levels also correlate with hospital mortality in adults following severe TBI [12]. A major role in inflammation is also played by TNF- α [13, 14]. In a rat model, the TNF- α antagonist Etanercept, administered early after TBI, reduced the secondary insults from oxidative stress and apoptosis with less neuronal loss [15]. The adaptive immune system, however, is less well described in TBI. Interleukin-17A produced mainly by specialised T cells, Th17 and $\gamma\delta$ T cells, plays a role in acute brain ischaemia, stroke [16] and multiple sclerosis [17]. It is also implicated in brain-gut signalling [18].

Here we describe the cytokine response in children with TBI compared to controls. As TBI has immunomodulating effects, we aimed to examine the cytokine profile following an additional stimulus of endotoxin in the serum of children with TBI compared to healthy controls at the time of injury. We repeated this at two weeks from injury, at timepoint when children with mTBI often appear to have recovered. Evoking and measuring an immune response in children who have sustained head injury may have a role in diagnostics, particularly in delineating recovery. This was explored using ratios of pro and anti-inflammatory markers.

Methods

Study Population

This study was approved by the Ethics Committees of Children's Health Ireland (CHI) at Tallaght (Ref: 2016-03 (21); approved 28.03.16) and CHI at Temple Street Dublin (Ref: 16.019; approved 23.03.16), Ireland. All families and participants received verbal and documented information on the study. Written consent was obtained prior to recruitment. The following children were enrolled: a) mTBI: Emergency department attendees with Glasgow Coma Scale 14/15; (b) sTBI: admitted to the Intensive Care with a Glasgow Coma Scale ≤ 8 c) Paediatric Controls: children attending for phlebotomy or day case procedures with normal results and clinical outcomes. Children in all groups were excluded if they had recent fever or evidence of infection. Demographics collected included learning disability, prior medical history, visual disorders, motion sickness, migraine history, prior traumatic brain injury, family history of concussion, migraine or mental health disorders in first degree relatives. Mechanism of injury, symptoms on presentation, at one hour and at the time of injury were recorded. A Child Sports Concussion Assessment Tool (Child-SCAT5), was recorded in children 5–12 years [19] and in children 13 years and older the SCAT5 was used[20] at the time of presentation. A post concussive symptom inventory (PCSI)

validated in children [21] was performed at the two-week assessment. Median time from injury at blood draw, was four hours with an interquartile range of (1.75-22hrs).

Sample preparation

Blood samples (3mL) for *in vitro* experiments were collected in a sodium citrate anti-coagulated blood tube and processed within two hours of phlebotomy. Whole blood was incubated at 37°C for 1 hour untreated (vehicle) or with Lipopolysaccharide (LPS; *E.coli* 0111:B4: SIGMA Life Science, Wicklow, Ireland) 10 ng/ml. After incubation the samples were centrifuged at 10,000rpm for 10 minutes at room temperature. The plasma supernatant was stored at -80°C for subsequent batch analysis [22].

Cytokine analysis

The following cytokines were evaluated using the MSD®MULTI-SPOT assay system from MesoScale Discovery, Rockville, MD, USA (www.meso-scale.com): IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, IFN- γ TNF- α [22]. Peripheral blood plasma was transferred to a 96 well MSD plate and these cytokines were assessed as per manufacturer's instructions. Assays were transferred to five U-PLEX platform plates with calibration curves showing expected signals, sensitivity precision, and accuracy. Sensitivities were < 1pg/ml for many assays. All assays used the same diluents, diluting linearly from 1-4-fold. Non-specific binding between assays was typically < 0.1%. The assay reproducibility was calculated using the intra variation of the standard curves was shown to be within an acceptable range. The median of the lower limit of detection for all 5 plate runs were as follows: IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, IFN- γ , TNF- α , 0.87, 1.72, 0.84, 0.38, 0.62, 1.15, 17.55, 2.39 respectively, with a closely aligned average value, demonstrating the reproducibility of the assay. Where the sample was below the lower limit of detection the value of the lower limit of detection for that assay was substituted.[23] No samples reached an upper limit of detection.

Statistics

Descriptive statistics were used to describe the demographics of the cohort. The Kolmogorov-Smirnov test was used to check normality. Statistical analysis was performed using Mann Whitney tests to compare mean ranks between two independent cohorts. Significance was defined as $p = 0.05$. Results shown are expressed as mean \pm standard error of the mean (SEM) unless otherwise stated. Receiver operator curves were generated from baseline unstimulated serum cytokine levels. Data was analysed with GraphPad Prism v.7.

Results

Clinical parameters

There were 238 samples collected from 208 children enrolled in this study including 110 children with TBI (mTBI $n = 104$; sTBI $n = 6$) and 98 paediatric controls. In the mTBI group 12 recruited patients declined phlebotomy and 30 mTBI children had repeat serology at 2 weeks. The mean (SD) age of children enrolled was as follows: severe TBI (7.9 \pm 5.0)y, mild TBI (11.2 \pm 4.0)y and controls (8.0 \pm 4.2)y. The

severe TBI cohort had a Glasgow Coma Scale (GCS) of less than 8 and required intubation, ventilation and an Intensive Care management. The causes of sTBI included falls from windows, car accidents, a crush injury and one fall. All had intracranial bleeding on CT imaging. Children in the mild TBI group had a GCS of 14/15 with the following causes: sports (n = 53; 51%), accidents including falls (n = 44; 42.3%) and road traffic accidents (n = 7; 6.7%). A loss of consciousness was described in 16.6% and 35.6% had amnesia. In the mild TBI group 26 (28.8%) underwent CT imaging and 4 were abnormal: depressed skull fracture and intracranial bleed; small left frontotemporal contusion/contracoup haemorrhagic lesion and non-displaced skull fractures (n = 2). In the mTBI cohort vomiting occurred in 41.8% with more than 3 episodes in 27.8% (Table 1).

Table 1
Demographics of children with TBI.

	Mild		Severe	
	n = 110 (%)		n = 6 (%)	
Cause of Injury:	n	%	n	%
Sport	53	51.0%	0	0
Accident	44	42.3%	6	100%
Road Traffic Accident	7	6.7%	0	0
Demographics				
Birthweight (mean +/-SD)	3.46 +/-0.59		3.62+/-0.21	
Age Mean +/-SD)	11.22+/-4.12		7.91 +/- 5.04	
Male	69	65.7%	5	50%
Special Care/Neonatal ICU admission	12	12.0%	0	0
Resus as infant	2	2.0%	1	16.6%
cerebral palsy	1	1.0%	0	0
Learning or Developmental disorder				
Speech Delay	11	10.8%	0	0
Special Needs Assistant at school	5	4.9%	1	16.6%
Autism Spectrum Disorder	3	2.9%	1	16.6%
Attention Deficit Hyperactivity Disorder	4	4.0%	0	0
Dyspraxia	3	2.9%	0	0
Dyslexia	11	10.8%	0	0
Any learning/developmental disability*	39	25.9%	1	16.6%
Medical conditions				
Epilepsy Diagnosis	1	1.0%	0	0
Previous Seizure	5	4.9%	0	0
Previous Concussion	27	27.0%	0	0
Depression or anxiety	10	9.8%	1	16.6%

*any learning /developmental disability includes Speech delay, a special needs assistant at school, Autistic spectrum disorder, Attention Deficit Hyperactivity Disorder, dyspraxia, dyslexia.

	Mild		Severe	
	n = 110 (%)		n = 6 (%)	
Travel sickness	14	14.7%	0	0
Wears glasses	16	16.3%	0	0
Suffers from headaches migraine	23	22.5%	0	0
Family History				
Family hx Migraine 1st degree relative	38	37.6%	2	33.2%
Family hx depression 1st degree relative	18	17.5%	1	16.6%
Family hx concussion 1st degree relative	17	17.2%	1	16.6%
*any learning /developmental disability includes Speech delay, a special needs assistant at school, Autistic spectrum disorder, Attention Deficit Hyperactivity Disorder, dyspraxia, dyslexia.				

Cytokines responses in Children with Traumatic brain injury versus controls at baseline

Interleukin-6 was raised in all children with TBI compared to controls and was significantly higher in sTBI versus mTBI ($p < 0.0001$; Fig. 2). All children with sTBI had IL-6 levels of > 20 pg/ml and no children with mTBI had values over 45pg/ml. At a cut-off value of 20pg/ml IL-6 was 100% sensitive and 99% specific for sTBI and 91% sensitive for mTBI detection but non-specific. Interferon- γ was decreased in sTBI ($p = 0.01$) but raised in mTBI ($p < 0.0001$; Table 2, Fig. 1). Although in children with sTBI IL-8, IL-10 IL-17A and TNF- α , did not change these cytokines were decreased in children with mTBI versus controls (Table 2 & Fig. 1–2). There were no significant differences seen in IL-2 or IL-4 in mild or sTBI compared to controls (Table 2 & Fig. 1). While patients with mTBI had significant but less potent increases in IL-6 concentrations than sTBI, they had a rise in IFN- γ , and reduction in IL-8, IL-10, IL-17A and TNF- α concentrations.

Table 2
Cytokines in children with TBI versus controls

Cytokine	Controls	Mild TBI	sTBI	p value*	p value**
IL-2	0.06 (0.75–2.80)	0.06 (0.86–1.34)	0.87 (0.87–0.87)	0.98	0.47
IL-4	0.80 (1.74–2.34)	0.69 (1.68–2.06)	1.72 (1.72–1.72)	0.34	0.66
IL-6	2.74 (2.19–3.28)	6.58 (4.71–8.45)	57.51 (19.32–95.70)	0.005	< 0.0001
IL-8	70.69 (61.19–80.18)	26.9 (21.02–32.97)	102.2 (3.70–200.8)	< 0.0001	0.38
IL-10	4.65 (3.72–5.58)	3.32 (1.59–5.05)	3.75 (1.09–6.41)	< 0.0001	0.72
IL-17A	14.98 (8.02–21.93)	1.48 (1.14–1.82)	1.39 (0.78–1.99)	< 0.0001	0.42
TNF-α	15.73 (13.51–17.95)	6.65 (5.14–8.15)	15.29 (2.33–28.24)	< 0.0001	0.82
IFN-γ	107.9 (75.63–140.1)	203.2 (-49.95–456.4)	17.55 (17.55–17.55)	< 0.0001	0.01

Cytokines to identify Traumatic brain injury in children at presentation

To further examine the utility of cytokine measurement and ratios of pro and anti-inflammatory markers in the setting of TBI, receiver operating characteristic curves were used to select patients with TBI compared to controls (Table 3, Supp Fig. 1). Severe TBI were distinguished from control patients by IL-6 with 100% sensitivity and specificity, with an Area Under the Curve (AUC) of 1. Mild TBI is less obvious clinically and biochemically and the presence of mild TBI was indicated by IL-6 with an AUC of 0.61 CI (0.54–0.691). The ratio of IL-6/IL-8 gave the highest AUC of 0.829 to select mild TBI. Since IL-10 and IL-17A were decreased in both mild and severe TBI compared to controls we examined the utility of using these to create a ratio which would be useful across the continuum from mild to severe. Using IL-6/IL-10 increased the AUC to predict mTBI to 0.801 CI (0.738–0.864). Using IL-6/IL-10/IL-17A the AUC was 0.832 at 0-4d.

Table 3
Receiver operator characteristic curves for cytokines of children with mild Traumatic brain injury and controls

Cytokine	mTBI at 0-4d AUC	mTBI at 10-14d AUC
Prediction of mTBI		
IL-6	0.61	0.464
TNF- α	0.204	0.163
IL6/IL8	0.829	0.744
IL6/IL10	0.801	0.686
IL6/IL-17A	0.744	0.621
IL6/IL10/IL-17A	0.832	0.746

Effects of ex-vivo LPS stimulation on Cytokine responses in children with TBI and controls

To challenge the immune system in the setting of TBI whole blood was stimulated with LPS. In sTBI, LPS stimulation caused a significant rise in IL-8, TNF- α and IL-17A from baseline ($p < 0.000001$, $p < 0.000001$, $p = 0.0048$). Baseline levels of IL-6 in the severe TBI cohort were high compared to both mTBI and controls and were not significantly increased with LPS (Fig. 2). Prior to stimulation with LPS, IL-8 and IL-10 levels were not significantly higher in sTBI compared to controls ($p = 0.38$, $p = 0.7$). Following LPS stimulation there was a significant increase in IL-8 and IL-10 levels in sTBI compared to stimulated control samples ($p = 0.035$, $p = 0.037$). In paediatric controls and in children with mTBI, LPS stimulation significantly increased IL-8, TNF- α and also IL-6 levels (< 0.0001 , < 0.0001 , < 0.0001 ; Fig. 2). In children with mTBI baseline IL-8 and TNF- α levels were low but were significantly responsive to LPS beyond the response seen for controls (Table 3). A significant response to LPS stimulation for IL-8 and TNF- α ($p < 0.0001$, $p = 0.0002$; Table 3) was seen in the serum taken from children with mTBI at 10–14 days from injury. Interleukin-2 and IL-4 did not respond to LPS stimulation in any group. Stimulation with LPS unmasked a hyperresponsiveness of the immune system in children who had both sTBI and mTBI. Children with mTBI specifically had lower levels of cytokines until stimulated with LPS.

Persistent inflammatory response

Due to the persistence of the immune response for an undefined period of time after TBI we followed the immune response in these patients for two weeks. In children with mTBI at 2 weeks, IL-17A, IL-8, IL-10 and TNF- α levels remained significantly decreased ($p = 0.009$, $p < 0.0001$, $p = 0.0006$, $p < 0.0001$, respectively) while IL-6 returned to baseline (Figs. 1 & 2). In mTBI, IL-8 responsiveness to LPS peaked at 0-4d but remained above control levels at 10–14 days (supp Table 1). In mTBI LPS induced a three-fold increase in IFN- γ levels on 0–4 day. This phenomenon was not seen at 2 weeks where LPS induced a decreased

response. There was a greater TNF- α production in response to LPS in mTBI at 10-14d than at 0-4d and versus controls (Table 3). At 10-14d from injury the serum of children with mild TBI showed persistent cytokine levels with a ROC curve using a ratio of IL-6/IL-10/IL-17A to give an AUC of 0.746. The cytokine production seen in children with mTBI persisted for two weeks as well as the response to LPS.

Discussion

At the time of injury, in children with both sTBI and mTBI, IL-6 was significantly elevated compared to controls. When stimulated ex-vivo with LPS, in sTBI and not mTBI, significant elevations of IL-8 and IL-10 were seen. The mTBI cohort showed significantly lower IL-8, IL-10 IL-17A and TNF- α at the time of injury. However, when stimulated with LPS, these children with mTBI had greater IL-8 and TNF- α responses, both in serum from the time of injury and serum at 2 weeks, showing persistent immune activation, at a time when the majority of children show clinical recovery. Serum taken two weeks from injury showed the same pattern of significantly decreased IL-17A, IL-8, IL-10 and TNF- α levels, while IL-6 had returned to baseline.

There are gaps in our understanding in how to modify the innate immune response to trauma to better the outcomes in TBI across the spectrum, particularly in children where the innate immune responses are different. Limiting the pro-inflammatory response and promoting anti-inflammatory properties is key to therapeutics. Defining these responses and timelines are important for secondary injury, particularly in the milder TBI children, not previously known to have persistent immune dysregulation. Early measurement of innate immune function may better help to risk stratify in mTBI.

Interleukin-6 was elevated in all children with TBI and predicted sTBI. IL-6/IL-10 ratio enhanced the prediction of mTBI relative to IL-6 alone. In sports related concussion IL-6 levels correlated with symptom burden in young adults [8]. While IL-6 is elevated in mTBI in adult studies it has not correlated with cognitive impairment[24], a common component of post concussive syndrome. Gill and colleagues showed significant increases in IL-6, IL-10 and TNF- α during blast exposure in military training [25]. In our study IL-6 elevations did not persist at two weeks. Interestingly exercise prior to injury in animal models have been shown to attenuate levels of IL-6 in response to mTBI [26], and also the effect of the injury [27].

In childhood sTBI is associated with increased serum IL-8 and predicted a worse outcome [7] In neonatal brain injury elevated IL-8 and IL-10 correlated with poor outcome and severity of injury [28]. Most TBI studies of cytokine responses have been in sTBI but not mTBI, where there is no overt intracranial bleeding, and the mechanism of injury is different. We demonstrated an opposite effect in this cohort with significantly lower levels of IL-8 and IL-10 in our mTBI cohort at baseline when compared to controls. An adult study looking at blast-related TBI in the military found similar responses to our study: IL-8 decreased from pre-deployment levels in those who suffered blast injury[29]. Interestingly this effect was more profound in those younger than 25 years. This may be an effect of age or may also suggest the response to all brain injury is not on a continuum.

There was a significant and sustained decrease in IL-17A following TBI. Only in sTBI did LPS mediate an IL-17A response to stimulation. Interleukin-17A is associated with TBI severity and also progression in multiple sclerosis. It has a role in mediating the blood brain barrier [30]. A severe TBI model in rats showed increased IL-17 production [31]. The role of the adaptive immune system in TBI, particularly in repeated mTBI needs further clarification.

Two weeks from injury there was a sustained decrease in IL-8, IL-10 IL-17A and TNF- α in the mTBI cohort. Animal studies demonstrate persistent immune dysfunction in severe TBI [3] and chronic changes associated with repeated head injury [32]. The mouse model of head injury showed chronic persistent changes in thymic and T cell function, neutrophil and monocyte function, and proinflammatory cytokine production including TNF- α , at 60 days [3]. In moderate/severe blast injury there was a reduction in IL-10, IL-17A and TNF- α even at a year from injury reflecting persistent inflammation [33]. Following neonatal encephalopathy children have persistent immune dysfunction much longer, at school-age[4]. Jeschke and colleagues demonstrated altered immune response in the three years following a severe physical burn injury in children [34]. The response of the immune system over time to one TBI and repeated insults may be amenable to immunomodulation.

Immunomodulatory effects of TBI are demonstrated in both cohorts. Provocative testing with LPS stimulation of samples from children with TBI unmasks immune dysregulation and may aid diagnostics. sTBI had significantly elevated IL-8 and IL-10 response to LPS while mTBI had a significant and sustained IL-6 and IL-8 response to LPS challenge, at time of injury and at two weeks. The greater TNF- α response at 10–14 days was specific to mTBI, suggesting priming. Prior studies of TNF- α responsive to LPS looked only at sTBI and not mTBI. A blunted TNF- α response in sTBI to LPS stimulation has been previously demonstrated in sepsis and trauma in children [35, 36]. This phenomenon results in increased nosocomial infections[37]. Our study is the first to look at children with mTBI/concussion which shows priming of the TNF- α response to LPS at two weeks, with an opposite and greater response to LPS challenge, at time when the majority of children appear to have recovered.

Innate immune function in children is distinctly different to adults. Ageing is associated with low grade chronic systemic inflammation with elevated IL-6 and C-reactive protein [38]. Studying the effects of TBI in children naïve to chronic disease offers a unique opportunity to look at TBI in isolation. Understanding the pathophysiological and post inflammatory changes associated with paediatric TBI may facilitate the understanding of potential new drug therapies in the initial and chronic phases of TBI. Even the use and timing of basic anti-inflammatory medication is poorly understood. This study was limited by the small number of sTBI, but the large number in the mTBI cohort was a strength in this under studied population.

Conclusion

This study demonstrated immune dysfunction not only in sTBI but also in mTBI. It established that immune dysfunction is persistent following paediatric mTBI. Interleukin-6 was elevated across the spectrum of TBI. The effect of TBI on systemic inflammation warrants serial follow up for months and

years. Evidence of injury in mTBI is occult, usually described subjectively by symptom report. A strong biomarker of mTBI has alluded scientific research, however provocative immune testing may be most beneficial. Further validation of these cytokines is key to understanding the mechanisms that are also a target of immunomodulatory therapy.

Abbreviations

CT: Computerised tomography

GCS: Glasgow coma scale

IFN- γ : Interferon- γ

IL: Interleukin

LPS: lipopolysaccharide

mTBI: mild traumatic brain injury

PCSI: post concussive symptom inventory

SCAT: Sports concussion assessment tool

sTBI: severe traumatic brain injury

TBI: Traumatic brain injury

TNF- α : Tissue necrosis factor- α

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committees of Children's Health Ireland (CHI) at Tallaght (Ref: 2016-03 (21); approved 28.03.16) and CHI at Temple Street Dublin (Ref: 16.019; approved 23.03.16), Ireland. Informed consent was obtained from patients and/or parents.

Consent for publication:

Not applicable

Availability of data and materials

The experimental data used to support the findings of this study are available from the corresponding author upon request.

Competing interests

The authors have no conflict of interest to declare.

Funding: This study was funded by the National Children's Hospital Fund [206965], Tallaght, Dublin, Ireland

Author's contributions:

The manuscript is being submitted on behalf of all the authors and is the original work of all authors. ER was responsible for recruitment, sample acquisition, lab experiments, analysis and was responsible for writing the main draft of the manuscript. LK and DH added expert laboratory assistance. LK, DH, DMC, CS, ED, AL, GB were responsible for patient recruitment, sample acquisition, reviewing and editing the manuscript. LK TB and EM were key in study design, supervising the research and its outcomes and providing crucial editorial assistance. All authors had editorial license to review and re-draft the manuscript, and all contributors had to approve the final edit. All authors are accountable for the accuracy and scientific integrity of this work.

Acknowledgements

The patients and parents who took part in this study.

References

1. Ryan E, Bolger T, Barrett MJ, Blackburn C, Okafor I, McNamara R, Molloy EJ: **Paediatric Head Injury and Traumatic Brain Injury.***Ir Med J* 2020, **113**:94.
2. Koepsell TD, Rivara FP, Vavilala MS, Wang J, Temkin N, Jaffe KM, Durbin DR: **Incidence and descriptive epidemiologic features of traumatic brain injury in King County, Washington.***Pediatrics* 2011, **128**:946-954.
3. Ritzel RM, Doran SJ, Barrett JP, Henry RJ, Ma EL, Faden AI, Loane DJ: **Chronic Alterations in Systemic Immune Function after Traumatic Brain Injury.***J Neurotrauma* 2018, **35**:1419-1436.
4. Zareen Z, Strickland T, Eneaney VM, Kelly LA, McDonald D, Sweetman D, Molloy EJ: **Cytokine dysregulation persists in childhood post Neonatal Encephalopathy.***BMC Neurol* 2020, **20**:115.
5. Frugier T, Morganti-Kossmann MC, O'Reilly D, McLean CA: **In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury.***J Neurotrauma* 2010, **27**:497-507.
6. Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, Whalen MJ, DeKosky ST: **Comparison of the interleukin-6 and interleukin-10 response in children after severe traumatic brain injury or septic shock.***Acta Neurochir Suppl* 1997, **70**:96-97.
7. Lo TY, Jones PA, Minns RA: **Combining coma score and serum biomarker levels to predict unfavorable outcome following childhood brain trauma.***Journal of Neurotrauma* 2010, **27**:2139-

2145.

8. Nitta ME, Savitz J, Nelson LD, Teague TK, Hoelzle JB, McCrea MA, Meier TB: **Acute elevation of serum inflammatory markers predicts symptom recovery after concussion.***Neurology* 2019, **93**:e497-e507.
9. Sribnick EA, Hensley J, Moore-Clingenpeel M, Muszynski JA, Thakkar RK, Hall MW: **Nosocomial Infection Following Severe Traumatic Injury in Children.***Pediatr Crit Care Med* 2020, **21**:443-450.
10. Rodney T, Osier N, Gill J: **Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: A review.***Cytokine* 2018, **110**:248-256.
11. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G, Ongini E: **Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage.***Eur J Neurosci* 2000, **12**:2265-2272.
12. Schneider Soares FM, Menezes de Souza N, Liborio Schwarzbald M, Paim Diaz A, Costa Nunes J, Hohl A, Nunes Abreu da Silva P, Vieira J, Lisboa de Souza R, More Bertotti M, et al: **Interleukin-10 is an independent biomarker of severe traumatic brain injury prognosis.***Neuroimmunomodulation* 2012, **19**:377-385.
13. Yang GY, Gong C, Qin Z, Liu XH, Lorris Betz A: **Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice.***Brain Res Mol Brain Res* 1999, **69**:135-143.
14. Shohami E, Bass R, Wallach D, Yamin A, Gallily R: **Inhibition of Tumor Necrosis Factor Alpha (TNF α) Activity in Rat Brain is Associated with Cerebroprotection after Closed Head Injury.***Journal of Cerebral Blood Flow & Metabolism* 1996, **16**:378-384.
15. Hasturk AE, Gokce EC, Yilmaz ER, Horasanli B, Evirgen O, Hayirli N, Gokturk H, Erguder I, Can B: **Therapeutic Evaluation of Tumor Necrosis Factor-alpha Antagonist Etanercept against Traumatic Brain Injury in Rats: Ultrastructural, Pathological, and Biochemical Analyses.***Asian J Neurosurg* 2018, **13**:1018-1025.
16. Li HL, Kostulas N, Huang YM, Xiao BG, van der Meide P, Kostulas V, Giedraitis V, Link H: **IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat.***J Neuroimmunol* 2001, **116**:5-14.
17. McGinley AM, Sutton CE, Edwards SC, Leane CM, DeCoursey J, Teixeira A, Hamilton JA, Boon L, Djouder N, Mills KHG: **Interleukin-17A Serves a Priming Role in Autoimmunity by Recruiting IL-1 β -Producing Myeloid Cells that Promote Pathogenic T Cells.***Immunity* 2020, **52**:342-356.e346.
18. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johnner C, Wekerle H, Krishnamoorthy G: **Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.***Nature* 2011, **479**:538-541.
19. Davis GA, Purcell L, Schneider KJ, Yeates KO, Gioia GA, Anderson V, Ellenbogen RG, Echemendia RJ, Makdissi M, Sills A, et al: **The Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5): Background and rationale.***Br J Sports Med* 2017, **51**:859-861.
20. Echemendia RJ, Broglio SP, Davis GA, Guskiewicz KM, Hayden KA, Leddy JJ, Meehan WP, Putukian M, Sullivan SJ, Schneider KJ, McCrory P: **What tests and measures should be added to the SCAT3**

and related tests to improve their reliability, sensitivity and/or specificity in sideline concussion diagnosis? A systematic review.*British Journal of Sports Medicine* 2017, **51**:895.

21. Sady MD, Vaughan CG, Gioia GA: **Psychometric characteristics of the postconcussion symptom inventory in children and adolescents.***Arch Clin Neuropsychol* 2014, **29**:348-363.
22. Huggard D, Kelly L, Ryan E, McGrane F, Lagan N, Roche E, Balfe J, Leahy TR, Franklin O, Doherty DG, Molloy EJ: **Increased systemic inflammation in children with Down syndrome.***Cytokine* 2020, **127**:154938.
23. Shoari N, Dube JS: **Toward improved analysis of concentration data: Embracing nondetects.***Environ Toxicol Chem* 2018, **37**:643-656.
24. Sun Y, Bai L, Niu X, Wang Z, Yin B, Bai G, Zhang D, Gan S, Sun C, Wang S, et al: **Elevated Serum Levels of Inflammation-Related Cytokines in Mild Traumatic Brain Injury Are Associated With Cognitive Performance.***Front Neurol* 2019, **10**:1120.
25. Gill J, Motamedi V, Osier N, Dell K, Arcurio L, Carr W, Walker P, Ahlers S, Lopresti M, Yarnell A: **Moderate blast exposure results in increased IL-6 and TNFalpha in peripheral blood.***Brain Behav Immun* 2017, **65**:90-94.
26. Febbraio MA, Pedersen BK: **Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?***Exerc Sport Sci Rev* 2005, **33**:114-119.
27. Anderson V, Manikas V, Babl FE, Hearps S, Dooley J: **Impact of Moderate Exercise on Post-concussive Symptoms and Cognitive Function after Concussion in Children and Adolescents Compared to Healthy Controls.***Int J Sports Med* 2018, **39**:696-703.
28. O'Hare FM, Watson RW, O'Neill A, Segurado R, Sweetman D, Downey P, Mooney E, Murphy J, Donoghue V, Molloy EJ: **Serial cytokine alterations and abnormal neuroimaging in newborn infants with encephalopathy.***Acta Paediatr* 2017, **106**:561-567.
29. Rusiecki J, Levin LI, Wang L, Byrne C, Krishnamurthy J, Chen L, Galdzicki Z, French LM: **Blast traumatic brain injury and serum inflammatory cytokines: a repeated measures case-control study among U.S. military service members.***J Neuroinflammation* 2020, **17**:20.
30. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, Sireci G, Fournie JJ, Dieli F: **Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells.***Blood* 2011, **118**:129-138.
31. Li T, Zhang YM, Han D, Hua R, Guo BN, Hu SQ, Yan XL, Xu T: **Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.***NeuroMolecular Medicine*, **19**:541-554.
32. Loane DJ, Kumar A, Stoica BA, Cabatbat R, Faden AI: **Progressive neurodegeneration after experimental brain trauma: association with chronic microglial activation.***J Neuropathol Exp Neurol* 2014, **73**:14-29.
33. Chen Y, Huang W, Constantini S: **The Differences between Blast-Induced and Sports-Related Brain Injuries.***Front Neurol* 2013, **4**:119.
34. Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC, Williams FN, Kraft R, Suman OE, Mlcak RP, Herndon DN: **Long-term persistence of the pathophysiologic response to severe burn injury.***PLoS One* 2011,

6:e21245.

35. Muszynski JA, Nofziger R, Moore-Clingenpeel M, Greathouse K, Anglim L, Steele L, Hensley J, Hanson-Huber L, Nateri J, Ramilo O, Hall MW: **Early Immune Function and Duration of Organ Dysfunction in Critically Ill Children with Sepsis.***Am J Respir Crit Care Med* 2018, **198**:361-369.
36. Muszynski JA, Nofziger R, Greathouse K, Nateri J, Hanson-Huber L, Steele L, Nicol K, Groner JI, Besner GE, Raffel C, et al: **Innate immune function predicts the development of nosocomial infection in critically injured children.***Shock* 2014, **42**:313-321.
37. Holland MC, Mackersie RC, Morabito D, Campbell AR, Kivett VA, Patel R, Erickson VR, Pittet JF: **The development of acute lung injury is associated with worse neurologic outcome in patients with severe traumatic brain injury.***J Trauma* 2003, **55**:106-111.
38. Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, Fernández-Tajes J, Pásaro E, Laffon B, Valdiglesias V: **Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis.***Geroscience* 2020.

Figures




Figure 1

Cytokines: (a) Interleukin 2 (IL)-2, (b) IL-4, (c) IFN γ and (d) IL-17A responses in Paediatric Traumatic brain injury. Serum of children with mild TBI (mTBI) at the time of presentation and at 2 weeks as well as children with severe TBI (sTBI) at baseline and, in response to LPS. Values were expressed as pg/ml. Samples size (Vehicle: n= 104 controls, n= 98 mTBI at 0-4d, n= 29 mTBI at 10-14d, n= 6 severe TBI. LPS: n= 11 controls, n= 18 mTBI at 0-4d, n= 9 mTBI at 10-14d, n= 4 severe). *p \leq 0.05*, **p<0.01, ***p<0.001, ##p<0.01.

****p <0.0001, patient cohort compared to controls. # = p<0.05 response to LPS from baseline. (a) and (b) there was no statistical difference between groups. (c) **** p < 0.0001 mTBI at baseline compared to controls, ** p = 0.0053 mTBI at 10-14d compared to controls, * p = 0.01 severe compared to controls (d) ** p = 0.0097 control compared to mTBI at 10-14d, **** p <0.0001 control compared to mTBI at 0-4d, ## p = 0.0048 sTBI pre and post LPS stimulation.




Figure 2

Cytokines: (a) Interleukin (IL)-6, (b) IL-8, (c) TNF α and (d) IL-10 responses in Paediatric Traumatic brain injury Serum of children with mild TBI (mTBI) at the time of presentation and at 2 weeks as well as children with severe TBI (sTBI) at baseline and in response to LPS. Values expressed as pg/ml. Samples size (Vehicle: n= 104 controls, n= 98 mTBI at 0-4d, n= 29 mTBI at 10-14d, n= 6 severe TBI. LPS: n= 11 controls, n= 18 mTBI at 0-4d, n= 9 mTBI at 10-14d, n= 4 severe). *p <0.05, **p<0.01, ***p<0.001, ****p <0.0001, patient cohort compared to controls. #p <0.05 response to LPS from baseline. (a) ** p = 0.005 mTBI 0-4d compared to controls, **** p <0.0001 control compared to sTBI at baseline, ## p = 0.001 controls pre and post LPS stimulation. #### p < 0.0001 mTBI 0-4d pre and post LPS. **p = 0.0015 controls compared to sTBI within LPS group. (b) **** p < 0.0001 mTBI 0-4d compared to controls, **** p < 0.0001 mTBI at 10-14d compared to controls, * p = 0.035 controls compared to sTBI in response to LPS. # p = 0.02 controls pre and post LPS, # p = 0.02 sTBI pre and post LPS #### p < 0.0001 mTBI pre and post LPS #### p < 0.0001 mTBI at 10-14d pre and post LPS. (c) **** p < 0.0001 mTBI 0-4d compared to controls, **** p < 0.0001 mTBI at 10-14d compared to controls ## p = 0.009 sTBI pre and post LPS ### p = 0.0001 mTBI at 10-14d pre and post LPS #### p < 0.0001 mTBI pre and post LPS, LPS #### p < 0.0001 controls pre and post LPS. (d) **** p < 0.0001 mTBI 0-4d compared to controls, *** p = 0.0004 mTBI at 10-14d compared to controls, * p = 0.037 controls compared to sTBI within LPS group.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementalfigure.docx](#)
- [Supplementaltable.docx](#)